Date:28 December, 2017

Organovo announces the FDA has granted orphan drug designation for the Company’s treatment of alpha-1

28 December 2017 – 

Organovo Holdings (NASDAQ:ONVO) announces that the FDA has granted orphan drug designation for the Company’s treatment of alpha-1 antitrypsin deficiency (“A1AT”) with its 3D bioprinted liver therapeutic tissue.

Among the benefits of Orphan Drug status is a seven-year period of market exclusivity for the indication, if approved.

A1AT is a rare inherited disorder that severely damages the lungs and liver.

Shares are up 10% premarket on robust volume.

 

The original story can be found here: https://seekingalpha.com/news/3320031-organovo-receives-odd-treatment-alphaminus-1-antitrypsin-deficiency